$
12.990
-0.38(-2.842%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.860
Open
13.350
VWAP
--
Vol
3.01M
Mkt Cap
591.62M
Low
12.900
Amount
--
EV/EBITDA(TTM)
76.24
Total Shares
43.70M
EV
634.61M
EV/OCF(TTM)
175.21
P/S(TTM)
3.08
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
58.86M
+19.13%
--
--
56.16M
+15.44%
--
--
52.61M
+9.8%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Axogen, Inc. (AXGN) for FY2025, with the revenue forecasts being adjusted by -0.27% over the past three months. During the same period, the stock price has changed by -19.72%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.27%
In Past 3 Month
Stock Price
Go Down
down Image
-19.72%
In Past 3 Month
5 Analyst Rating
up Image
84.76% Upside
Wall Street analysts forecast AXGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXGN is 24.00 USD with a low forecast of 21.00 USD and a high forecast of 30.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image
84.76% Upside
Current: 12.990
sliders
Low
21.00
Averages
24.00
High
30.00
Canaccord
Buy
downgrade
$26 -> $24
2025-05-13
Reason
Canaccord lowered the firm's price target on AxoGen to $24 from $26 and keeps a Buy rating on the shares. The firm updated its model to reflect Q125 results and the subsequent 10Q release. As a reminder, the company reiterated FY25 revenue and gross margin guidance on its Q125 call.
Raymond James
Jayson Bedford
Outperform
downgrade
$25 -> $21
2025-05-08
Reason
Lake Street
Frank Takkinen
Strong Buy
Initiates
$30
2025-03-17
Reason
Citizens Capital Markets
David Turkaly
Buy
Reiterates
$26
2025-03-05
Reason
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$24
2025-03-05
Reason
Citizens Capital Markets
Constantine Davides
Buy
Maintains
$20 → $26
2025-02-26
Reason
Citizens JMP raised the firm's price target on AxoGen to $26 from $20 and keeps an Outperform rating on the shares. The company's sales were in line with its January preannouncement and well above the firm's estimates, with initial 2025 guidance also above the firm's expectations, positive net income in Q4 and guided to cash flow positivity in 2025, the analyst tells investors in a research note. The firm says its bullish stance on AxoGen is based on the belief that it has truly differentiated products -- including the recently launched AxoGuard HA+ nerve protector and the Avive+ resorbable soft tissue matrix -- for nerve protection and repair.

Valuation Metrics

The current forward P/E ratio for AxoGen Inc (AXGN.O) is -326.10, compared to its 5-year average forward P/E of -63.58. For a more detailed relative valuation and DCF analysis to assess AxoGen Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-63.58
Current PE
-326.10
Overvalued PE
76.29
Undervalued PE
-203.44

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
17.86
Current EV/EBITDA
22.78
Overvalued EV/EBITDA
123.71
Undervalued EV/EBITDA
-87.99

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
3.23
Current PS
2.72
Overvalued PS
4.64
Undervalued PS
1.82

Financials

Annual
Quarterly
FY2025Q1
YoY :
+17.36%
48.56M
Total Revenue
FY2025Q1
YoY :
-63.57%
-1.66M
Operating Profit
FY2025Q1
YoY :
-42.22%
-3.83M
Net Income after Tax
FY2025Q1
YoY :
-46.67%
-0.08
EPS - Diluted
FY2025Q1
YoY :
+1.71%
-13.84M
Free Cash Flow
FY2025Q1
YoY :
-8.74%
71.94
Gross Profit Margin - %
FY2025Q1
YoY :
-99.19%
-0.11
FCF Margin - %
FY2025Q1
YoY :
-50.75%
-7.90
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 115.69% over the last month.
Sold
0-3
Months
802.0K
USD
9
3-6
Months
364.5K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 2920% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.5M
Volume
1
6-9
Months
50.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
833.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

AXGN News & Events

Events Timeline

2025-05-08 (ET)
2025-05-08
07:48:12
AxoGen appoints Hartley as CFO
select
2025-05-08
07:27:35
AxoGen sees FY25 revenue growth 15%-17%
select
2025-05-08
07:27:02
AxoGen reports Q1 adjusted EPS 2c, consensus 2c
select
Sign Up For More Events

News

5.0
06-11NASDAQ.COM
Insider Sale: Director at $AXGN Sells 4,073 Shares
3.0
04-24Newsfilter
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
4.0
03-17Benzinga
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Sign Up For More News

FAQ

arrow icon

What is AxoGen Inc (AXGN) stock price today?

The current price of AXGN is 12.99 USD — it has decreased -2.84 % in the last trading day.

arrow icon

What is AxoGen Inc (AXGN)'s business?

arrow icon

What is the price predicton of AXGN Stock?

arrow icon

What is AxoGen Inc (AXGN)'s revenue for the last quarter?

arrow icon

What is AxoGen Inc (AXGN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for AxoGen Inc (AXGN)'s fundamentals?

arrow icon

How many employees does AxoGen Inc (AXGN). have?

arrow icon

What is AxoGen Inc (AXGN) market cap?